JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia

Leukemia

Volumn 24, Issue 10, 2010, Pages 1809-1813

  Andrikovics, H ^a   Nahajevszky, S ^b   Koszarska, M ^a   Meggyesi, N ^a   Bors, A ^a   Halm, G ^b   Lueff, S ^b   Lovas, N ^b   Matrai, Z ^b   Csomor, J ^b   Rasonyi, R ^b   Egyed, M ^c   Varkonyi, J ^d   Mikala, G ^b   Sipos, A ^b   Kozma, A ^b   Adam, E ^b   Fekete, S ^b   Masszi, T ^b   Tordai, A ^a  

^a Molecular Diagnostics Laboratory   (Hungary)

^b Szent Laszlo Hospital   (Hungary)

^c Kaposi Mor County Hospital   (Hungary)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUNGARY; LETTER; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 77958013704     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.172     Document Type: Letter

References (9)

1. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450-454.
2. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41: 455-459.
3. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL et al. JAK2 haplotype is a major risk factor for the development of myelo-proliferative neoplasms. Nat Genet 2009; 41: 446-449.
4. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010; 24: 110-114.
5. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105-109.
6. Guglielmelli P, Biamonte F, Spolverini A, Pieri L, Isgrò A, Antonioli E et al. Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia 2010; 24: 1533-1537.
7. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Siragusa S et al. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. Leukemia 2010; 24: 859-860.
8. Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K et al. The JAK2 46/1 haplotype predisposes to MPL mutated myeloproliferative neoplasms. Blood 2010; 115: 4517-4523.
9. Campbell PJ. Somatic and germline genetics at the JAK2 locus. Nat Genet 2009; 41: 385-386.